Ovid Therapeutics
OVID

$1.02

10.53%

Market Cap: $72.4M

About: Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.

Employees: 40

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

188% more call options, than puts

Call options by funds: $23K | Put options by funds: $8K

6.29% less ownership

Funds ownership: 60.54% [Q1] → 54.25% (-6.29%) [Q2]

9% less funds holding

Funds holding: 80 [Q1] → 73 (-7) [Q2]

12% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 25

33% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 21

77% less capital invested

Capital invested by funds: $131M [Q1] → $29.6M (-$101M) [Q2]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$1.20

18%

upside

Avg. target

$3.03

197%

upside

High target

$5

390%

upside

7 analyst ratings

6 positive

86%

1 neutral

14%

0 negative

0%

HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 121 / 288 met price target	194%upside $3	Buy Reiterated	19 Aug 2024
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 121 / 288 met price target	194%upside $3	Buy Reiterated	26 Jul 2024
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 121 / 288 met price target	194%upside $3	Buy Reiterated	2 Jul 2024
BTIG Thomas Shrader 40% 1-year accuracy 2 / 5 met price target	390%upside $5	Buy Maintained	18 Jun 2024
B. Riley Securities Kalpit Patel 38% 1-year accuracy 5 / 13 met price target	194%upside $3	Buy Maintained	18 Jun 2024

See Analyst Rankings

Financial journalist opinion

Based on 12 articles about OVID published over the past 30 days

Zacks Investment Research

Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why

Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why

Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm

Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm

Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm

Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm

Ovid Therapeutics Inc Shareholders Encouraged To Join Fraud Investigation With Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Ovid Therapeutics Inc Shareholders Encouraged To Join Fraud Investigation With Schall Law Firm

Ovid Therapeutics Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Ovid Therapeutics Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Zacks Investment Research

Ovid Therapeutics (OVID) Q2 Earnings and Revenues Surpass Estimates

Ovid Therapeutics (OVID) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to loss of $0.18 per share a year ago.

Ovid Therapeutics (OVID) Q2 Earnings and Revenues Surpass Estimates

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today reported business updates and financial results for the second quarter ended June 30, 2024.

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

See News Rankings